Cutting-edge medicine, tailored to you

• Mechanotransduction (Converting Mechanical Force into Biological Signal)
• The science: Shockwaves are nonlinear, high-pressure acoustic waves with a rapid rise time to peak pressure, short duration (<10 ms), and a low tensile phase. Their therapeutic effect in musculoskeletal use is NOT the direct mechanical impact used in kidney-stone lithotripsy, but mechanotransduction -cells convert the acoustic mechanical stimulus into intracellular biochemical signaling cascades that drive repair.
• The analogy: The shockwave is like knocking on a dormant construction crew's door. The knock itself does not build anything, but it wakes the crew and triggers them to start working. The old lithotripsy model was about breaking things apart; the modern biological model is about sending a wake-up signal.
• Why this matters: ESWT is not primarily mechanically breaking up scar tissue or calcium in most musculoskeletal applications; it delivers a controlled mechanical stimulus that reprograms cells toward a regenerative state.

• Neoangiogenesis (New Blood Vessel Formation)
• The science: ESWT upregulates early expression of VEGF, eNOS, and PCNA, driving neovascularization and improved regional blood flow to hypovascular tissue.
• The analogy: Tendons and ligaments are like neighborhoods at the end of a poorly maintained road. ESWT triggers construction of new roads (blood vessels) so oxygen, nutrients, and repair cells can reach the area.
• Why this matters: Tendinopathy, non-union fractures, and avascular necrosis involve compromised blood supply, making this angiogenic effect central to the regenerative rationale.

• Cellular Proliferation and Differentiation
• The science: ESWT stimulates proliferation, migration, and differentiation of stem cells, fibroblasts, tenocytes, osteoblasts, and their precursors. In tenocytes, it increases collagen production while decreasing matrix metalloproteinases and inflammatory cytokines.
• The analogy: ESWT calls in and activates the repair workforce, tells them to multiply, and directs them to lay down organized collagen while calling off the demolition crew (MMPs).
• Why this matters: This shifts tissue from a degenerative, catabolic state toward an anabolic, regenerative one.

• Analgesia (Pain Modulation)
• The science: ESWT relieves pain through peripheral neuroregulation, reduction of pro-inflammatory mediators, hyperstimulation analgesia, increased serotonin in the dorsal horn with descending inhibition, and modulation of central pain networks.
• The analogy: ESWT works like resetting an overactive alarm system -temporarily disrupting malfunctioning sensory signaling, turning down the spinal-cord volume, and quieting the brain's amplified pain response.
• Why this matters: Pain relief often precedes structural healing and is frequently a primary clinical endpoint.

• Bone Remodeling and Osteogenesis
• The science: ESWT activates osteogenesis through osteoblast differentiation and proliferation, stimulates periosteal bone formation, supports subchondral bone rebuilding, and reduces osteoclast activity.
• The analogy: In a stalled fracture or crumbling subchondral foundation, ESWT restarts the building project -recruiting the bricklayers (osteoblasts) while calling off the wrecking crew (osteoclasts).
• Why this matters: This is the rationale for ESWT in delayed/non-union fractures, stress fractures, avascular necrosis, and selected subchondral applications.

• Does NOT primarily work by mechanically 'breaking up' scar tissue, adhesions, or calcium deposits. In musculoskeletal use, the dominant mechanism is biological mechanotransduction rather than mechanical fragmentation.
• Does NOT deliver identical results across all conditions. Evidence is strongest for chronic plantar fasciitis, mixed/moderate for calcific rotator cuff disease and lateral epicondylitis, and lower or inconsistent for patellar and Achilles tendinopathy.
• Does NOT require radial to be 'gentle' and focused to be 'strong'; that energy dichotomy is outdated.
• Does NOT reliably show one device type to be superior across indications.

• Standardized condition-specific optimal parameters (EFD, pulse count, frequency, session number, and interval).
• Whether radial or focused is superior for a given indication.
• Safety data in vulnerable populations such as pregnancy, pediatrics, and anticoagulated patients.
• Long-term durability of structural improvement in many tendinopathies.

• 'ESWT breaks up scar tissue and calcium like a jackhammer.' TRUTH: The dominant therapeutic model is mechanotransduction, angiogenesis, cell activation, and remodeling.
• 'Focused shockwave is always more powerful and better than radial.' TRUTH: No consistent superiority has been established.
• 'It works instantly.' TRUTH: Benefit often develops over weeks to months through a regenerative cascade.
• 'Proven for everything.' TRUTH: Evidence strength varies substantially by indication.

• Vitamin C500-1,000 mg/day
• Collagen peptides10-15 g/day
• Magnesium (glycinate)400-600 mg/day
• Vitamin D31,000-3,000 IU/day
• Protein1.2-1.6 g/kg/day
• Glycine3-5 g/day
• BPC-157, TB-500, GHK-Cu synergistic

• Platelet Growth-Factor Release
• The science: PRP is an autologous blood-derived concentrate of platelets. When activated, the platelets release growth factors, including PDGF and TGF-β, that signal cell migration, extracellular-matrix production, and tissue repair.
• The analogy: Platelets are like emergency repair packets carried in the blood. PRP concentrates those packets and places more repair signals at the injury site.
• Why this matters: PRP supplies signaling molecules, not replacement tissue or stem cells. Its effect depends on the condition being treated and the composition of the PRP preparation.

• Concentration-Dependent Biologic Effect
• The science: PRP products are not identical. Platelet concentration, leukocyte content, activation method, and injection site can change the biological and clinical response.
• The analogy: Calling every preparation "PRP" is like calling every cup of coffee the same even though the strength and ingredients can be completely different.
• Why this matters: A 2025 meta-analysis of randomized trials found that platelet concentration influenced the durability and clinical importance of outcomes in knee osteoarthritis.
• Evidence: https://pubmed.ncbi.nlm.nih.gov/39751394/ https://pubmed.ncbi.nlm.nih.gov/34812863/

• Does NOT inject stem cells. PRP is concentrated plasma and platelets from the patient's own blood.
• Does NOT guarantee cartilage regrowth or permanent structural repair.
• Does NOT work identically across all preparations or conditions.

• The optimal platelet concentration, leukocyte content, activation method, and injection schedule for every indication.
• Whether symptom improvement in a specific condition is accompanied by meaningful long-term tissue regeneration.

• "PRP is stem-cell therapy." TRUTH: PRP is a platelet concentrate, not a stem-cell product.
• "One PRP injection regrows cartilage." TRUTH: Controlled evidence is stronger for symptom and function outcomes than for reliable cartilage restoration.
• "All PRP is the same." TRUTH: Platelet concentration and preparation characteristics influence results.

• https://pubmed.ncbi.nlm.nih.gov/39751394/
• https://pubmed.ncbi.nlm.nih.gov/34812863/

• Vitamin D31,000-3,000 IU/day
• Vitamin C500-1,000 mg/day
• Omega-3 EPA/DHA2-3 g/day
• Zinc15-30 mg/day
• Protein1.5 g/kg/day, Glycine 3-5g, 15mg collagen, BPC, TB500, GHK-CU synergistic

• MSCs in BMAC do not primarily rebuild tissue themselves. Instead, they secrete a complex cocktail of growth factors, cytokines, and extracellular vesicles that recruit and direct the body's own repair cells to the injury site. This secretome promotes proliferation of endogenous stem cells, attracts repair cells via chemoattraction, prevents scar tissue formation, inhibits cell death, stimulates new blood vessel formation, and modulates the inflammatory response. This insight was so significant that Arnold Caplan, who originally coined "mesenchymal stem cells," recommended rebranding them as "medicinal signaling cells." (Fitzsimmons et al., Stem Cells Int. 2018; Fan et al., Cell Mol Life Sci. 2020)
• Think of MSCs as generals, not soldiers. They don't swing hammers or lay bricks. They arrive at the battlefield, survey the damage, and issue orders through chemical signals: recruiting the body's own repair cells, telling them where to go, what to build, and when to stop fighting. The general's value is not in doing the labor but in coordinating the entire reconstruction effort.

• BMAC contains significantly higher concentrations of interleukin-1 receptor antagonist (IL-1Ra) than any form of PRP. IL-1Ra directly blocks the IL-1 receptor, one of the primary drivers of cartilage degradation and joint inflammation in osteoarthritis. The IL-1Ra/IL-1beta ratio in BMAC consistently exceeds the threshold required to inhibit destructive IL-1beta activity. Beyond IL-1Ra, MSCs inhibit effector T-cell activation, modulate regulatory T-cell activity, polarize macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, and suppress TNF-alpha, IFN-gamma, and IL-6 while upregulating IL-10 and IL-4. Bone marrow mononuclear cells respond to inflamed synovial fluid with a brief NF-kB spike followed by sustained activation of pro-resolving pathways including the mevalonate pathway and PPAR-gamma signaling, driving lasting resolution of inflammation. (Ziegler et al., Am J Sports Med. 2019; Cassano et al., KSSTA. 2018; Menarim et al., Front Immunol. 2021)
• Joint inflammation is like a civil war inside the joint: immune cells are attacking the body's own cartilage. BMAC acts as a diplomatic negotiator who arrives and does three things: disarms the aggressors (blocks IL-1 with IL-1Ra), converts enemy combatants into peacekeepers (M1->M2 macrophage polarization), and establishes a ceasefire agreement (shifts the cytokine balance from pro-inflammatory to anti-inflammatory). The negotiator doesn't rebuild the city; but no rebuilding can happen until the fighting stops.

• When applied to cartilage defects, especially after microfracture, BMAC provides growth factors (VEGF, PDGF, TGF-beta, BMPs) and MSCs that facilitate cartilage repair. Animal and clinical studies show that defect filling is achieved with fibrocartilage or "hyaline-like" cartilage, though true hyaline cartilage regeneration has not been consistently demonstrated. Comparative trials have shown BMAC to be equivalent to or better than microfracture alone, and equivalent to matrix-induced autologous chondrocyte implantation (MACI) for focal chondral lesions. (Hamula & Mandelbaum, Arthroscopy. 2021; Cavinatto et al., Arthroscopy. 2019)
• A cartilage defect is like a bare patch in a lawn. Microfracture alone is like poking holes in the soil to let grass roots grow; it works, but slowly and incompletely. Adding BMAC is like spreading fertilizer, seed, and topsoil over the holes. The growth factors are the fertilizer, the MSCs are the seeds, and the platelets create the scaffolding (topsoil) that holds everything in place while new growth takes root.

• BMAC delivers connective tissue progenitors (CTPs) directly to the repair site, and the concentration of CTPs delivered has been directly correlated with the therapeutic effect; patients who received higher MSC counts had better healing rates. MSCs at the tendon-bone interface secrete factors that promote organized collagen deposition and reduce the formation of disorganized scar tissue. In rotator cuff repair, BMAC augmentation resulted in significantly lower retear rates on 1-year MRI (18% vs. 57%, P<.001), and a landmark study by Hernigou et al. found 87% of MSC-treated rotator cuffs intact at 10 years versus only 44% of controls. (Cole et al., Am J Sports Med. 2023; Di Matteo et al., Stem Cells Int. 2021)
• Tendon healing without BMAC is like a construction crew working without a foreman; they'll build something, but it may be disorganized and weak (scar tissue). BMAC provides the foreman (MSCs) who directs the workers (fibroblasts) to lay down collagen fibers in an organized pattern, resulting in a stronger, more functional repair. The more experienced foremen you send (higher CTP count), the better the final structure.

• BMAC injected into subchondral bone (beneath the cartilage surface) has been shown to significantly reduce bone marrow edema on MRI, suggesting it can address the subchondral bone pathology that drives pain in osteoarthritis. (Kon et al., KSSTA. 2021)
• If cartilage is the floor of a house, subchondral bone is the foundation. You can resurface the floor all day, but if the foundation is crumbling and waterlogged (bone marrow edema), the floor will keep cracking. Subchondral BMAC injection is like injecting stabilizing resin into a crumbling foundation; it addresses the root cause beneath the surface.

BMAC is a pure stem-cell injection.

It is not. BMAC is a mixed concentrate. Laboratory analysis shows it can enrich total nucleated cells, platelets, growth factors, and small mesenchymal stem/stromal and progenitor-cell populations.

• Different concentration systems can produce different cellular and growth-factor profiles. (Schafer et al., J Transl Med. 2019) MYTH: BMAC reliably regrows normal joint cartilage.

That has not been established. In a randomized, blinded, placebo-controlled knee osteoarthritis study, BMAC did not outperform saline for pain at 12 months, and quantitative MRI did not show a significant cartilage regenerative effect. (Shapiro et al., Cartilage. 2019) MYTH: Every BMAC preparation is basically the same.

It is not standardized across preparation systems. Cell counts, progenitor-cell populations, platelets, and growth factors can vary with collection and concentration methods. (Schafer et al., J Transl Med. 2019)

• Vitamin D31,000-3,000 IU/day
• Vitamin C500-1,000 mg/day
• Magnesium (glycinate)400-600 mg/day
• Zinc15-30 mg/day, , BPC, TB500, GHK-CU synergistic

• Hydrodissection uses ultrasound guidance to place fluid around an entrapped nerve, creating a tissue plane between the nerve and surrounding structures.
• The goal is to reduce mechanical tethering and improve the nerve's ability to glide. The injectate itself may also affect symptoms, depending on what fluid is used. Analogy: Think of the nerve as a cable that is stuck to the lining around it. Hydrodissection uses fluid to gently open space around the cable so it can move more freely.

• Most randomized clinical evidence is for median nerve hydrodissection in carpal tunnel syndrome.
• Randomized trials have found that ultrasound-guided perineural 5% dextrose can improve pain and disability, including compared with corticosteroid, and a later randomized trial found 10 mL of 5% dextrose more effective than normal saline for pain and median nerve size at 12 weeks. (Wu et al., Ann Neurol. 2018; Eyvaz et al., Am J Phys Med Rehabil. 2025)
• Different ultrasound-guided approaches to median nerve hydrodissection have also been compared in randomized trials. (Chen et al., Int J Med Sci. 2021) BOTTOM LINE: Hydrodissection is a mechanical, ultrasound-guided nerve-release technique, not one specific drug treatment. The strongest clinical evidence is currently in carpal tunnel syndrome.

Hydrodissection is just another name for a steroid injection.

It is not. Hydrodissection describes the ultrasound-guided mechanical separation of a nerve from surrounding tissue using fluid. Studies have used different injectates, including 5% dextrose, saline, and corticosteroid.

If symptoms improve, it proves scar tissue was permanently broken apart.

Clinical improvement does not prove permanent removal of adhesions. Trials show improvements in symptoms and, in some studies, nerve size, but the benefit can reflect both mechanical hydrodissection and effects of the injectate.

More fluid always gives a better result.

That has not been established. Different fluid volumes and techniques have been studied, and there is no universal evidence-based volume that is best for every nerve or entrapment.

• Alpha-lipoic acid600 mg/day
• Vitamin C500-1,000 mg/day
• Collagen peptides10-15 g/day
• Magnesium (glycinate)400-600 mg/day, , BPC, TB500, ARA-290, GHK-CU synergistic

• proliferation of endogenous stem/progenitor cells,
• chemoattraction of repair cells to the injury site,
• anti-fibrosis (preventing scar tissue),
• anti-apoptosis (preventing cell death),
• and angiogenesis (new blood vessel formation)

High-volume injection is proven to work by permanently stripping away abnormal blood vessels and nerves.

That is a proposed mechanism, not a proven explanation. In a randomized placebo-controlled study of chronic midportion Achilles tendinopathy, high-volume injection did not significantly change Doppler blood flow, and changes in Doppler flow were not associated with clinical outcome. (van Oosten et al., Clin J Sport Med. 2022) MYTH: High-volume injection without corticosteroid is clearly better than usual care for chronic Achilles tendinopathy.

That has not been shown consistently. A randomized controlled trial found no added symptom benefit from high-volume injection without corticosteroid compared with placebo injection plus usual care at 24 weeks. (van der Vlist et al., BMJ. 2020) MYTH: A larger injection volume automatically means a stronger treatment.

There is no established dose-response showing that more volume produces better clinical outcomes. Technique, injectate, rehabilitation, and the condition being treated all matter.

• Vitamin C500-1,000 mg/day
• Collagen peptides10-15 g/day
• Magnesium (glycinate)400-600 mg/day
• Alpha-lipoic acid600 mg/day, BPC, TB500, ARA-290, GHK-CU synergistic